Last updated: Oct 4, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07226856 | 2 | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | Unknown mechanism |
| NCT07491445 | 3 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | KRAS(ON) -- RAS inhibitor (daraxonrasib) combined with chemotherapy |
| NCT06885697 | 1 | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | Mesothelin -- chimeric antigen receptor T cell therapy (CAR T) |
| NCT01174121 | 2 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Tumor infiltrating lymphocytes (TILs) plus PD-1 blockade -- adoptive cell therapy plus immune checkpoint inhibitor |
| NCT07490301 | 2, 3 | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma | c-Met -- antibody-drug conjugate (telisotuzumab adizutecan) + chemotherapy |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 20 |
| Tianjin Medical University Cancer Institute and Hospital | 17 |
| Ruijin Hospital | 13 |
| Zhejiang University | 12 |
| West China Hospital | 8 |
Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 1, 2027 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma | MEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC) |
| Dec 16, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | PSCA -- radiolabeled antibody fragment for imaging (radioconjugate) |
| Dec 2026 | NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer | Multiple DNA synthesis and topoisomerase enzymes -- multi-agent chemotherapy (antimetabolite and topoisomerase inhibitor) |
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Oct 15, 2026 | NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | CDK7 -- kinase inhibitor (small molecule) |
| Oct 15, 2026 | NCT07828236 | PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA | Listeria monocytogenes expressing Listeriolysin O and Tetanus Toxin fragment -- bacterial vector vaccine (biological) |
| Oct 10, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
You've seen the pancreatic cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.